Form 8-K - Current report:
SEC Accession No. 0001104659-24-127231
Filing Date
2024-12-10
Accepted
2024-12-10 16:45:27
Documents
17
Period of Report
2024-12-10
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2430677d1_8k.htm   iXBRL 8-K 29818
2 EXHIBIT 99.1 tm2430677d1_ex99-1.htm EX-99.1 13160
3 EXHIBIT 99.2 tm2430677d1_ex99-2.htm EX-99.2 23625
7 GRAPHIC tm2430677d1_ex99-2img01.jpg GRAPHIC 19235
8 GRAPHIC tm2430677d1_ex99-2img02.jpg GRAPHIC 9996
  Complete submission text file 0001104659-24-127231.txt   294518

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA sls-20241210.xsd EX-101.SCH 3042
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE sls-20241210_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sls-20241210_pre.xml EX-101.PRE 22378
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2430677d1_8k_htm.xml XML 3688
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 241539110
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)